Voluntary announcement four clinical studies selected for presentation at 2026 ESMO congress: CMG901 (AZD0901) clinical trial results selected as LBA for proffered paper presentation at Presidential Symposium, MRG007 clinical trial results selected as LBA for rapid oral presentation, and two other studies selected for rapid oral presentation
Filed with HKEX · Stock code 2157 · · 4 pages · English
乐普生物 LEPU BIOPHARMA LEPU BIOPHARMA CO., LTD. 樂普生物科技股份有限公司 (A joint stock company incorporated in the People's Republic of China with limited liability) (Stock Code: 2157) VOLUNTARY ANNOUNCEMENT FOUR CLINICAL STUDIES SELECTED FOR PRESENTATION AT 2026 ESMO CONGRESS: CMG901 (AZD0901) CLINICAL TRIAL RESULTS SELECTED AS LBA FOR PROFFERED PAPER PRESENTATION AT PRESIDENTIAL SYMPOSIUM, MRG007 CLINICAL TRI
Lepu Biopharma Co. Ltd. on 6ix
Earlier from Lepu Biopharma
- 2026 Interim Report
- BioDlink and Lepu Biopharma Celebrate Successful Launch of the World's First EGFR-Targeting ADC Drug, Marking a Major Milestone in Mutual Collaboration in Biologics CMC
- BioDlink Congratulates Lepu Biopharma on Securing Approval for the World's First Approved EGFR-Targeted ADC
Later from Lepu Biopharma
All Lepu Biopharma news releasesFollow Lepu Biopharma into a list and get an email when it puts out news.
Follow Lepu Biopharma